Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan

High-dose melphalan (HDM) is an essential component in the treatment of patients with multiple myeloma (MM). Few data are available regarding genetic polymorphisms associated with patient outcome or toxicity in this setting. To identify such polymorphisms, we performed a retrospective analysis, geno...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2010-08, Vol.45 (8), p.1316-1324
Hauptverfasser:	Dumontet, C, Landi, S, Reiman, T, Perry, T, Plesa, A, Bellini, I, Barale, R, Pilarski, L M, Troncy, J, Tavtigian, S, Gemignani, F
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aldehyde dehydrogenase Apoptosis Bone marrow BRCA1 protein Breast cancer Cell Biology Cell cycle Cytochrome P450 Deoxyribonucleic acid DNA DNA repair DNA Repair - genetics Dosage and administration Drug dosages Drug metabolism Drug therapy Female Gene polymorphism Genes Genetic aspects Genetic polymorphisms Genotype Genotyping Hematology Humans Identification and classification Induction therapy Internal Medicine Male Medicine Medicine & Public Health Melphalan Melphalan - administration & dosage Metabolism Middle Aged Mucositis Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Nucleotides original-article Patients Pharmaceutical Preparations - metabolism Pharmacogenetics - methods Polymorphism, Genetic Polymorphism, Single Nucleotide Public Health Repair Retrospective Studies Single-nucleotide polymorphism Stem cell transplantation Stem Cells Subgroups Toxicity Treatment Outcome XRCC1 protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	High-dose melphalan (HDM) is an essential component in the treatment of patients with multiple myeloma (MM). Few data are available regarding genetic polymorphisms associated with patient outcome or toxicity in this setting. To identify such polymorphisms, we performed a retrospective analysis, genotyping single nucleotide polymorphisms (SNPs) with the arrayed primer extension (APEX) technology in 169 patients having received HDM for MM. We analyzed 209 SNPs in 95 genes involved in drug metabolism, DNA repair, cell cycle and apoptosis. SNPs in ABCB1 , CYP3A4 and TP53BP2 were associated with response to VAD induction therapy ( P
ISSN:	0268-3369 1476-5365
DOI:	10.1038/bmt.2009.335